Other News To Note
Thursday, February 21, 2013
• Gilead Sciences Inc., of Foster City, Calif., said it reached an agreement in principle with Teva Pharmaceuticals Industries Ltd., of Jerusalem, settling litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), Gilead's treatment for HIV infection and chronic hepatitis B virus.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.